Microfluidics Intl (fka MFLU)

[cfoofme]

Microfluidics International Corporation Announces $5.0 Million Convertible Debt Financing
Friday November 14, 4:02 pm ET


NEWTON, Mass.--(BUSINESS WIRE)--Microfluidics International Corporation (OTCBB: MFLU - News) announced today that the Company has secured $5.0 million of financing via a convertible debenture from a strategic investor.
ADVERTISEMENT


“This financing provides significant working capital to support the Company’s strategic plan for growth, including research and development initiatives to bring new products and services to the market for our customers,” said Michael C. Ferrara, President and Chief Executive Officer of Microfluidics.

The convertible debenture has a seven-year term with an annual interest rate of 9%. The holder of the debenture, at its option, may elect to convert the debt into Microfluidics common stock at a price per share of $1.25. In addition to the debt, warrants were issued to the holder to purchase additional common stock of the Company. The warrants are in two tranches which, if exercised, could provide approximately $20.0 million in additional financing to Microfluidics. The first tranche is exercisable in whole or in part at $2.00 per share for up to a 40% equity stake in the Company and the second tranche is exercisable in whole or in part at $3.00 per share for up to a 50% equity stake in the Company, assuming full conversion of the convertible debenture. As part of the agreement, the holder is entitled to a seat on the Microfluidics Board of Directors.

“In these economic times, we believe securing our financial future is a required step on behalf of all our stakeholders,” said Brian E. LeClair, Executive Vice President and Chief Financial Officer of Microfluidics. “Obtaining additional financing through this convertible debenture was the next step in building our capital structure and meets our working capital requirements to finance the growth of the Company.”

Microfluidics was advised by Covington Associates, a specialty investment banking firm serving consumer, business service, industrial, healthcare and technology companies throughout the country.

[cfoofme]

NEWTON, Mass.--(BUSINESS WIRE)--Microfluidics, a division of Microfluidics International Corporation (OTCBB: MFLU - News), announces the availability of several new services designed to enhance customer success and assist in customer innovation. These new services build on the deep technology, process and applications expertise that Microfluidics has developed through its 25 years of experience with thousands of customer applications, including the company's hands-on work with formulations at the Microfluidics Technology Center.
ADVERTISEMENT


The new services include process consulting, customized in-house seminars and training, and preventive maintenance contracts. Process consulting and customized seminars/training are delivered by Microfluidics’ Chief Technology Officer, Mimi Panagiotou, and the company’s technical staff members. Preventive maintenance is provided by highly-skilled field service engineers.

“Because our customers’ challenges and opportunities continue to evolve, we’re expanding the ways in which we support their technical innovations and subsequent commercial success,” noted Mary Anne North, Microfluidics’ Vice President of Customer Success. “Through these new services, we are helping our customers to understand and capitalize on new technologies, and to optimize their development and production processes.”

These new services further expand Microfluidics’ portfolio of customer services and support. Prior to purchase, Microfluidics provides qualified prospects with complimentary processing of a lab sample at its Microfluidics Technology Center. It also offers on-site demonstrations, regional seminars and rental options. After its customers invest in a Microfluidizer® processor, Microfluidics ensures their successful ongoing use via pharmaceutical-specific acceptance testing, startup and installation training, technical services and a full range of parts.

Process consulting

Through its process consulting services, Microfluidics helps its customers to develop processes for nanomaterial production and then optimize those processes while scaling up from lab to pilots and full-scale production. Its highly-trained technical staff members have advised many customers and provide consulting services ranging from proof of concept to optimization and scale-up.

Examples of topics for process consulting include:


Assistance with formulation development and material characterization
Proof of concept for single formulations addressing a variety of process parameters (shear rate, temperature, etc.) This may include hands-on lab work.
Product optimization for multiple formulations. This may include hardware optimization and lab work.
Scale-up, including hardware optimization on a large scale
Process intensification
Customized in-house seminars and training

Microfluidics’ technical staff members stay current on nanotechnology developments and a wide range of other promising technologies and applications, and use that expertise to deliver customized in-house seminars and training.

Examples of topics for seminars and training include:


Seminars tailored for each customer covering all aspects of the Microfluidizer technology and discussing its use in relation to the customer’s unique needs. This may include hands-on training if requested.
Briefings on specific applications or new technologies, tailored for each customer on topics such as bio-pharma, energy chemicals, digital inks, etc.
Overview seminars on nanotechnology (synthesis, processing, applications), possibly including outside speakers
Preventive maintenance contracts

Microfluidics’ preventive maintenance contracts provide customers with the ease of pre-arranging their annual preventive maintenance, through single- or multiple-year contracts, in order to ensure the longevity and optimal performance of their Microfluidizer processors. A Microfluidics preventive maintenance visit to a customer site by a skilled field service engineer includes processor inspection, replacement of designated parts, a performance test, a written report of processor condition and recommendations, and brief training in various processor procedures.

About Microfluidics

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.





Contact:
Gray & Rice Public Relations
Katie DePorter, 617-747-1795
[e-mail]

http://ih.advfn.com/p.php?pid=nmona&cb=1223389807&article=28552530&symbol=NB%5EMFLU

[cfoofme]

Microfluidics Expands The M-110P Bench-Top Microfluidizer® Processor Line With Three New Products
September 16, 2008

M-110P series offers unique machines for chemical applications

Newton, MA - Microfluidics has expanded its range of product offerings by adding three new Microfluidizer® bench-top processors to its M-110P family. The new M-110P-20, M-110P-20S and M-110PS deliver all the features and benefits of the ground-breaking M-110P bench-top lab machine, while adding new capabilities and benefits to address the unique needs of the chemical industry.

M-110P family processors are used to create stable emulsions and the dispersion of incompatible chemicals or ingredients. As droplet size decreases and particles are more uniformly dispersed, the effectiveness of product performance increases. Additionally, these high shear fluid processors can also be used to achieve high color strength and gloss, and to reduce the amount of volatile organic compounds by increasing water content. Narrow size distribution, achieved by using these machines, prohibits the clogging of tiny inkjet nozzles. The M-110P processors also work to ensure high formulation stability and longer shelf life.

Like the original model, the new additions to the M-110P family require no compressed air or cooling water for hydraulics; the units also operate reliably, quietly and efficiently, and require only a standard 20 amp single phase electrical outlet. A CE compatible version of all three models is also being introduced.

The M-110P-20 is a new mid-pressured version of the higher-pressured M-110P model. It operates at a lower pressure and lower cost, is able to deliver nanoemulsions, nanosuspensions, nanoencapsulations and nanodispersions at 20,000 psi or lower, and works with a 50 ml minimum sample size. The M-110P-20 harnesses the company's highly successful and time-tested ceramic interaction chamber to easily enable the production of nanoemulsions, nanosuspensions, nanoencapsulations and nanodispersions with the fewest number of passes.

The M-110PS and M-110P-20S Microfluidizer processors are designed to work with smaller minimum sample sizes of 25 ml. The M-110PS utilizes Microfluidics' diamond interaction chamber technology, while the M-110P-20S utilizes Microfluidics' ceramic interaction chamber technology, and both machines have a ceramic (Zirconia) plunger. All three new models include a glass reservoir for fast and accurate visual identification.

All products in the M-110P family allow flow rates starting at 110 ml/minute (95 ml/minute for CE versions) depending on process pressure, which is a higher flow rate than any comparable, competitive product. All results from this family of machines are guaranteed to be scaleable to pilot and/or production volumes.

About Microfluidics
Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

SOURCE: Microfluidics


http://www.chemicalonline.com/article.mvc/Microfluidics-M-110P-Bench-Top-Microfluidizer-0002

[cfoofme]

Microfluidics International Corporation Ticker Symbol Change
11:48a ET September 5, 2008 (Business Wire)
Microfluidics International Corporation (OTCBB: MFIC) today announced that the Company received notification from Nasdaq that the Company's name change as approved at its annual meeting in June has been officially registered with the exchange, effective September 5, 2008. The Company's name has been changed to Microfluidics International Corporation and the stock is now trading under the new ticker (OTCBB: MFLU). For additional information, please visit the Company's website at www.mficcorp.com

[cfoofme]

Microfluidics International Corporation Announces Second Quarter 2008 Results
8:00a ET August 12, 2008 (Business Wire)
Microfluidics International Corporation, (OTCBB: MFIC), an industry-leader in high-shear liquid processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries, today reported financial results for the second quarter of 2008.

Second Quarter Highlights

-- Recorded highest second quarter revenue in the Company's history of $4.4 million

-- Addressed working capital needs with signing of $2.5 million multi-year revolving credit line

-- Completed executive leadership team with the appointment of a new Executive Vice President and Chief Financial Officer, Chief Technology Officer, and Vice President of Customer Success

-- Finalized three year strategic plan focused on double-digit top line organic global growth

-- Changed name to Microfluidics International Corporation to enhance global branding

For the quarter ended June 30, 2008 the Company reported revenues of $4.4 million, an increase of 23.0% from $3.6 million in the second quarter of 2007 and a negative EBITDA of $(754,000) or $(0.07) per share for the second quarter of 2008 as compared to a negative EBITDA of $(82,000) or $(0.01) per share for the same period in 2007.

Net loss for the second quarter 2008 was $(790,000) or $(0.08) per share as compared to a net loss of $(107,000) or $(0.01) per share for the second quarter ended June 30, 2007.

The Company's order backlog as of June 30, 2008 was $2.7 million compared to backlog of $2.9 million as of June 30, 2007. The decrease in backlog was primarily a result of North American order timing delays of large production machines.

"Our focus on revenue growth, properly building the Company's infrastructure, and rounding out our leadership team remained our top priority this quarter," said Michael C. Ferrara, President and Chief Executive Officer. "We are not pleased with the EBITDA results for the quarter. However, we are in the process of addressing this issue on several fronts and we will align the operating expenses as required on our path to profitability. Strong performance with our large pharmaceutical customers, combined with our initial success in globally expanding our distribution resources are our plans to deliver top line results that will support our growth initiatives."

Brian E. LeClair, Executive Vice President and Chief Financial Officer, added, "Our EBITDA for the second quarter was below our expectations. The loss in the quarter was driven by a decline in our gross margins and an increase in operating expenses. The decline in margins was associated with sales of our lab units which were introduced in the previous quarter at lower margins and higher sales of the custom production machines. We have put corrective plans in place to address the margin decline that should bring our margins back in line with historical levels. Results were also adversely affected by an increase in operating expenses associated with building our leadership team and making investments in our future growth."

MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three Months Ended For The Six Months Ended June 30, June 30, -------------------------- ------------------------- 2008 2007 2008 2007 ------------- ------------ ------------ ------------ Revenues $ 4,374 $ 3,557 $ 7,896 $ 6,358 Cost of goods sold 2,225 1,453 3,834 2,646 ------------- ------------ ------------ ------------ Gross profit 2,149 2,104 4,062 3,712 ------------- ------------ ------------ ------------ Operating expenses: Research and development 572 438 1,062 974 Selling 1,196 984 2,128 1,808 General and administrative 1,175 805 2,118 1,483 ------------- ------------ ------------ ------------ Total operating expenses 2,943 2,227 5,308 4,265 ------------- ------------ ------------ ------------ Loss from operations (794) (123) (1,246) (553) Interest expense (6) (1) (10) (9) Interest income 10 17 21 38 ------------- ------------ ------------ ------------ Net loss $ (790) $ (107) $ (1,235) $ (524) ============= ============ ============ ============ Net loss per common share: Basic $ (0.08) $ (0.01) $ (0.12) $ (0.05) Diluted $ (0.08) $ (0.01) $ (0.12) $ (0.05) Weighted average number of common and common equivalent shares outstanding: Basic 10,267,981 10,180,413 10,267,981 10,151,749 Diluted 10,267,981 10,180,413 10,267,981 10,151,749
MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Balance Sheets (Unaudited - in thousands, except share and per share amounts) June 30, December 31, 2008 2007 ------------ ------------ ASSETS Current assets: Cash and cash equivalents $ 1,162 $ 756 Accounts receivable, net of allowance of $41 both at June 30, 2008 and December 31, 2007, respectively 2,250 2,582 Inventories 2,638 2,353 Prepaid and other current assets 688 281 ------------ ------------ Total current assets 6,738 5,972 Property and equipment, net 849 325 Patents and licenses, net 58 60 ------------ ------------ Total assets $ 7,645 $ 6,357 ============ ============ LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Revolving credit line $ 1,012 $ 262 Current maturities of long-term debt and obligations under capital lease - 65 Accounts payable 1,449 129 Accrued expenses 1,069 725 Customer advances 464 409 ------------ ------------ Total current liabilities 3,994 1,590 ------------ ------------ Total liabilities 3,994 1,590 ------------ ------------ Stockholders' equity: Common stock; $.01 par value; 20,000,000 shares authorized; 10,528,427 and 10,517,178 shares issued; 10,267,981 and 10,256,732 shares outstanding as of June 30, 2008 and December 31, 2007, respectively. 105 105 Additional paid-in capital 17,497 17,378 Accumulated deficit (13,263) (12,028) Treasury stock, 260,446 shares, at cost, as of June 30, 2008 and December 31, 2007 (688) (688) ------------ ------------ Total stockholders' equity 3,651 4,767 ------------ ------------ Total liabilities and stockholders' equity $ 7,645 $ 6,357 ============ ============
MICROFLUIDICS INTERNATIONAL CORPORATION U.S. GAAP TO Non-GAAP Measure Reconciliations and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (In thousands, except share and per share amounts) Quarter Ended Six Months Ended June 30, June 30, ------------------------- ------------------------- 2008 2007 2008 2007 ------------------------- ------------------------- Net loss $ (790) $ (107) $ (1,235) $ (524) Net interest income (4) (16) (10) (29) Depreciation and amortization 40 41 81 83 ------------------------- ------------------------- EBITDA (Non-GAAP Measure) $ (754) $ (82) $ (1,164) $ (470) ------------------------- ------------------------- Weighted average number of common and common equivalent shares outstanding: Basic: 10,267,981 10,180,413 10,267,981 10,151,749 Diluted: 10,267,981 10,180,413 10,267,981 10,151,749 EBITDA per common share (Non-GAAP Measure): Basic: $ (0.07) $ (0.01) $ (0.11) $ (0.05) Diluted: $ (0.07) $ (0.01) $ (0.11) $ (0.05)

Live Webcast

Microfluidics International Corporation will host a webcast at 8:30 a.m. ET today to discuss the quarterly results. To access the webcast, go to the Company's web site, www.mficcorp.com, and click on the webcast icon. If you do not have access to the Internet and wish to listen to the call, dial 888-679-8037 (international callers dial 617-213-4849). The participant passcode for this event is 84046982. An audio replay of the call will be available from 10:30 a.m. ET on Tuesday, August 12th until 11:59 p.m. ET on Tuesday, August 19th. The replay can be accessed by dialing 888-286-8010 (international callers dial 617-801-6888) and entering conference call ID # 91204941.

Safe Harbor for Forward Looking Statements

Certain statements in this press release contain "forward-looking statements." All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including the section of this press release entitled "Outlook"; any projections of earnings, revenue or other financial items relating to the Company, any statement of the plans, strategies and objectives of management for future operations; any statements concerning proposed future growth rates in the markets we serve; any statements of belief; any characterization of and the Company's ability to control contingent liabilities; anticipated trends in the Company's businesses; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "estimate," "intend," "continue," "believe," "expect," "anticipate," and other similar words. Although the Company believes that the expectations reflected in any forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties beyond the control of the Company. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to general economic conditions, geopolitical factors, future levels of general industrial manufacturing activity, future financial performance, market acceptance of new or enhanced versions of the Company's products, the pricing of raw materials, changes in the competitive environments in which the Company's businesses operate, the outcome of pending or future litigation and governmental proceedings and approvals, estimated legal costs, increases in interest rates, the Company's ability to meet its debt obligations, and risks and uncertainties listed or disclosed in the Company's reports filed with the Securities and Exchange Commission, including, without limitation, the risks identified under the heading "Risk Factors" set forth in the Company's Annual Report filed on Form 10-K. The Company does not intend, and undertakes no obligation, to update or alter any forward-looking statements.

EBITDA and Non-GAAP Measures

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies.

One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.

About Microfluidics International Corporation

Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.

SOURCE: Microfluidics International Corporation

Microfluidics International Corporation Brian E. LeClair, 617-969-5452 [e-mail] or FD Ashton Partners Michael Cummings, 617-897-1532 [e-mail]

[cfoofme]

Microfluidics International Corporation to Webcast Second Quarter Fiscal Year 2008 Results Earnings Conference Call August 12th
8:59p ET July 29, 2008 (Business Wire)
Microfluidics International Corporation (OTCBB: MFIC - News) announced today that it expects to release second quarter 2008 results on Tuesday, August 12, 2008, before the opening of the U.S. financial markets. A conference call will be held at 8:30 AM Eastern Time on Tuesday, August 12, 2008 to review the financial results and to outline progress on key 2008 strategic initiatives.

Michael C. Ferrara, President and Chief Executive Officer, and Brian E. LeClair, Executive Vice President and Chief Financial Officer, will review the second quarter financial results and accomplishments. To access the webcast, go to the Company's web site, www.mficcorp.com, on the day of the conference call and click on the webcast link.

If you do not have access to the Internet and wish to listen to the call, dial 888-679-8037 (international callers dial 617-213-4849). The participant passcode for this event is 84046982. An audio replay of the call will be available from 10:30 a.m. ET on Tuesday, August 12th until 11:59 p.m. ET on Tuesday, August 19th. The replay can be accessed by dialing 888-286-8010 (international callers dial 617-801-6888) and entering conference call ID # 91204941. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the webcast by accessing the following address: www.theconferencingservice.com/prereg/key.process?key=PNVFQ9C9E

[cfoofme]

Webcast link from another board:

By: sixersadvantcom
24 Jul 2008, 10:14 PM EDT
Msg. 12945 of 12947
(This msg. is a reply to 12944 by Baton.)
Jump to msg. #
Baton,

I just went back and listened to the 1st quarter CC again. Click on Webcast powered by Thompson to listen.

http://www.mficcorp.com/index.php?option=com_content&task=view&id=41&Itemid=39

Remember this call took place after the 2nd quarter was 1/2 over so Mike had a pretty good fix on the 2nd quarter at that time. Mike stated that after the 2nd quarter he thought he would have something to talk to institutional investors about. He also mentioned backlog. Then consider that they were able to increase the revolver at what looked like good terms to me in a difficult environment was very positive. I suspect that they had to show good revenue numbers for the 2nd quarter as part of the conditions to get the revolver done. I feel very good about this quarter and added a little this week to my already large position.

[cfoofme]

NANOTECHNOLOGY USED AS A WEAPON TO FIGHT CANCER

Submitted by Admin on June 30, 2008 - 15:06.
Category tags: Press release
The technique, part of the burgeoning field of nutraceuticals, involves creating nanoemulsions, or nano-sized capsules made from oil and water. The emulsions, which are so small they are measured in nanometers—or 1/100 of a meter—are then filled with various antioxidants or anti-cancer fighting compounds, and tests show they can reduce tumors in rats.

Researchers at the University of Massachusetts Lowell injected rats with neuroblastoma, so they would develop tumors, and then treated them with nanoemulsions containing antioxidants. They found that while the rats fed in the control group continued to develop tumors, the growth rate for those fed antioxidants was actually negative 65 percent, meaning the tumors actually shrank.

“They had about 70 percent total tumor regression,” said Professor Robert Nicolosi, director of UMass Lowell’s Center for Health and Disease Research.

When researchers exposed melanoma cancer cells to a nanoemulsion containing curcumin, an anti-cancer compound found in turmeric, cancer cell proliferation was greatly reduced, Nicolosi said. And when they used a nanoemulsion containing tamoxifen, a drug used to fight breast cancer, they just about eliminated the ability of the cells to proliferate—at least in a cell culture, Nicolosi said. Nanoemulsion delivery systems have been shown to increase the bioavailablity and efficacy of certain drugs. The advantage, particularly for some of the toxic compounds used in fighting cancer, is that less of that compound is needed to achieve the same effect. That means the patient would suffer fewer damaging side effects.

“There’s no question we’re reducing the toxicity when we use 10 to 20 times less,” Nicolosi said.
Umass has been using Microfluidizer materials processing equipment to develop the nutraceutical products. The equipment has helped standardize the size of the nanoemulsions, making them more commercially viable. Prior to the Microfluidizer, nanoemulsions came out in varying sizes, making them less effective and less likely to gain approval by the US Food and Drug Administration, according to Scott McMeil, director of the Nanotechnology Characterization Laboratory at SAIC-Frederick, Inc.

“Nanoemulsions have been around for several years, but they weren’t very stable. But with a Microfluidizer, it looks like it’s overcoming the stability issue,” McNeil said.

McNeil, whose company is subcontracted by the National Cancer Institute, said the FDA requires that a compound is stable before it will grant its seal of approval. Before researchers began using the Microfluidizer, the size of the various nanoemulsions might vary from five nanometers to five microns, in one solution, making the solution less stable.

“A company would not move forward with something that was that high risk,” McNeil said. “The Microfluidizer has opened up new opportunities, such as nanoemulsions.”

In order to create the nanoemulsion, scientists mix water, an emulsifier like lecithin, and an antioxidant or anti-cancer fighting compound, and then pour it into a Microfluidizer processor. The processor then compresses the solution and drives it through tiny microchannels, and then in a reaction chamber, it splits the solution into two streams, which collide with each other at extremely high speeds. The collision creates a nanoemulsion that has a long shelf life.

Researchers, such as UMass are also using the Microfluidizer processors to create foods, beverages, and nutritional supplements that can reduce inflammation or inhibit the intestines ability to absorb cholesterol, thus reducing blood cholesterol levels as well as the risk of heart disease.

Source information :
Contacts:
Robert Nicolosi, UMass/Lowell, 978-934-4501
Scott McNeil, SAIC-Frederick Inc., 301-846-6939

[cfoofme]

MFIC news:


http://www.azonano.com/news.asp?newsID=6791

[cfoofme]

http://ih.advfn.com/p.php?pid=nmona&cb=1213827796&article=26936982&symbol=NB%5EMFIC


http://ih.advfn.com/p.php?pid=nmona&cb=1213827905&article=26934736&symbol=NB%5EMFIC


Send stock manipulators to: [e-mail]-and to jail.

[cfoofme]

MFIC Corporation Changes Name to Microfluidics International Corporation




MFIC Corporation (OTCBB: MFIC) today announced that at the Company’s Annual Meeting held on June 17, 2008 shareholders voted to changes the Company’s name to Microfluidics International Corporation, effective June 18, 2008. The Company’s stock will continue to trade on the Over-the-Counter Bulletin Board (OTCBB) under the ticker MFIC. The Company’s website will be remain located at www.mficcorp.com.

“The Microfluidics’ name has successfully branded the Company’s products for more than 25 years and has significant recognition across our industry,” said Michael C. Ferrara, Chief Executive Officer of Microfluidics International Corporation. “The transformation of this Company is well under way and we believe that building upon the equity in the Microfluidics’ name directly supports our global growth strategy and best reflects our current and future business operations as a global leader in the design and manufacturing of high-shear processing and formulation equipment.” About Microfluidics International Corporation: Microfluidics International Corporation designs, manufactures and distributes proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics applies its more than 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics’ equipment customers.

Forward Looking Statement: Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to our plan to achieve, maintain and/or increase growth in revenue and/or market share, to achieve, maintain, and/or increase operating profitability, and/or to achieve, maintain, and/or increase net operating profitability. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by us to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to, the following risks and uncertainties: (i) whether the performance advantages of our Microfluidizer materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the timing of orders will significantly affect quarter to quarter revenues and resulting net income results for a particular quarter, which may cause increased volatility in our stock price, (iii) whether we will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to our ability to maintain compliance with the covenants and terms of our loan agreement with our senior lender, (iv) whether our Microfluidics Reaction Technology will be adopted by customers as a means of producing innovative materials in large quantities, (v) whether we are able to deploy prototype Microfluidics Reaction Technology systems for nanoparticle production and then manufacture and introduce commercial production Microfluidics Reaction Technology equipment, and (vi) whether we will achieve a greater proportion of our sales in the future through the sale of advanced processor production systems

[cfoofme]

Microfluidics Reaction Technology (MRT) Article for Consideration for Publication

http://www.pharmalive.com/News/index.cfm?articleid=548536&categoryid=15


Next Generation Nanosuspension Processing for the Delivery of Non-Soluble Drugs

BOSTON, June 12, 2008--Roughly half of all new drugs in development are poorly soluble and often associated with low bioavailability. Among the most promising solutions to this challenge are nanosuspensions, defined as a colloidal dispersion of submicron pure drug particles that are stabilized by surfactants. The small particle size provides increased surface area which can significantly improve bioavailability. Additionally, nanosuspensions can be formulated to deliver high concentrations of active pharmaceutical ingredients (API), overcoming the dosage limitations of other nanoparticles formulations like emulsions and liposomes.

A new generation of nanosuspension processing equipment is enabling pharmaceutical and biotechnology companies to develop and ultimately manufacture difficult-to-formulate insoluble drugs. It has been demonstrated that Microfluidics Reaction Technology (MRT), a highly successful development program at Microfluidics Corporation (MFIC), headquartered in Newton, Mass., can create high purity nano-particles to sizes not achievable with conventional particle size reduction methods. This new technology could potentially unlock numerous drugs, vaccines and drug delivery systems that could not be formulated or efficaciously administered in the past.

Bottom-Up versus Top-Down

The MRT creates nanosuspensions through the precipitation of crystals. This solvent/anti-solvent crystallization is commonly called a "bottom-up" technique, because particles are grown, beginning with crystallization of individual molecules. To do this, the API is dissolved into a solvent, and then this solution is subsequently mixed with an anti-solvent to cause precipitation/crystallization. The technology introduces uniform mixing in the nanometer scale of species that are present in the chemical or physical processes which enables nanoparticles to be formed and the rates of the processes to be expedited.

In contrast, the conventional "top-down" process takes larger particles and breaks them apart to achieve submicron particle sizes. Various techniques are employed, such as wet-milling, homogenization, and micronization. Most often these top-down processes cannot produce enough energy to break through nature's barrier to reduce particles smaller than the primary crystal size which varies with each material of interest. This limitation is a roadblock that prevents a growing number of critical formulations from becoming available to the marketplace.

The key to MRT is the processing conditions in the MicrofluidizerR processor reaction chamber where the precipitation/crystallization takes place. The short reaction time (i.e. dwell time) inside the high speed, high pressure, and high shear environment, forces the reactants to interact at a nanoscale level. By intensifying various processes, and by expediting the rate of chemical reaction, the processor's continuous microreactor generates high throughput.

This new technology is advantageous compared to other bottom-up techniques that already exist. For example, a laboratory technician can certainly perform solvent/anti-solvent crystallization in a glass beaker at atmospheric pressure, but this process is difficult to control and to scale. Also, the product can be inconsistent and can contain unacceptable levels of impurities and crystalline polymorphs that provide no pharmacological benefit.

The MRT Process

To cover a broad range of applications, the current MRT program consists of two reactors; the Microfluidics Mixer Reactor (MMR) for very fast reactions, and a coaxial feed reactor (Co-Reactor) that introduces the multiple reactant streams coaxially and allows the predetermined residence time for slower reactions. Both reactors are based on an impinging jet design where the highly-pressurized reactant solutions are forced into narrow channels and result in collision of the streams inside the reaction zone. Using feedback from flow sensors, computer control of inlet valves ensures proper stoichiometry in the reaction zone.

The residence times in the Microfluidizer processor chamber can range from a few hundred microseconds to a few hundred milliseconds. It is the levels and the localized nature of the energy dissipation that create a uniform mixture of the reactants in the nanometer level.

The patented Microfluidizer Mixer-Reactor (MMR) system is a high-performing, continuous chemical reactor utilizing multiple reactant fluid streams. In most conventional chemical reactors, inadequate mixing and mass-transfer rates limit the value and performance of a fast chemical reaction. As a result, product yields are low, and unwanted by-products are produced. Building upon basic Microfluidics technology, computer controlled flow rates of multiple streams of pressurized reactants are brought together in a proprietary MMR mixing chamber with residence times of a few hundred microseconds to a few hundred milliseconds. By optimizing the fast chemical reactions required in specific chemical processes, MMR enables the production of uniform nanoparticles on a continuous basis with phase purity previously unachievable with conventional batch reaction technology.

The Co-Reactor allows for precise control of the feed rate, reactant ratios, and mixing intensity and location of liquid reactants through a coaxial feed system. For the slower reactions, which comprise the majority of applications that are encountered, the co-reactor has clearly demonstrated to be more effective in producing optimally-sized, consistent nanosuspensions than standard particle size reducing methods for a variety of drugs using solvent and anti-solvent crystallization.

Unlike other multi-stream mixer reactor systems, the co-reactor pumps the multiple streams of pressurized reactants (the API dissolved into the solvent and the anti-solvent) through a coaxial feed system to the Microfluidizer processor reaction chamber. The flow of each of the reactants is metered by a peristaltic positive-displacement pump, and the precisely-controlled mixing ratio can vary from 1:1 to 40:1.

Each stream in the Microfluidizer processor is pressurized in the range of 5,000 to 40,000 psi and led into an inlet channel a few millimeters long with a cross-sectional area in the range of 75-200 microns. Fluid velocities between three and 30 m/sec are achieved. Jets are then formed, reaching velocities in the 200-400 m/sec range. The channels are formed in diamond or ceramic constructs to handle a wide variety of product media.

Both systems are scalable. Parallel jets can be employed - operate under identical conditions - and should process tens of liters per minute.



Figure 1. Principal of operation of Microfluidics Reaction Technology.


The technology is designed to prevent any reacting prior to the reactants entering the interaction chamber. However, for some applications, it may be desirable to allow the controlled mixing of the inlet streams in a macromixing zone before entry into the inlet channels. Liquid mixing occurs for a few milliseconds in these channels, creating a small amount of microcrystalline product nuclei to seed the reaction in the reaction zone, if necessary.

Requirements of the pressures, channel dimensions, reaction zone dimensions and exit channel dimensions are experimentally optimized to accommodate the specific kinetics of the reaction being conducted. Bulk fluid temperature rise in the system between five and 20 Celsius depending on process pressure, and heating or cooling either before or after reaction can be provided.

Post-reaction processing may be necessary or desirable for some reactions to prevent crystal growth or to alter crystal morphology (length/diameter ratios of needle-shaped crystals, for example). Agglomeration is a natural post-reaction event. It can be minimized by dilution of the product stream. Alternately, the product can be redispersed at a later time.

Experimental Results

MRT has been successful in producing stable nanosuspensions with exceptionally small particle sizes for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory, with molecular weights ranging from 228-750 Amu.

Control experiments were performed for comparison purposes, using conventional "top-down" particle reduction methods. These conventional methods were not able to achieve particle sizes as small as those created using MRT, regardless of the number of processing cycles.





API

Microfluidics Reaction Technology (single pass)

Control: Crystallization

Control: Particle Size Reduction (25 passes)

Azithromycin

50-100 nm



Oxycarbazepine

767 nm

5,000 nm x 20,000 nm

1,200 nm

Norfloxacin

180 nm

3,000 nm x 1,000,000 nm

428 nm

Loratadine

90-332 nm



Figure 2: Crystallization Results using Microfluidics Reaction Technology

Note: Figures are median particle size.

The experiments used the solvents DMSO or NMP, and water served as the antisolvent. The surfactants, Solutol (BASF) and INUTEK (Orafti) were also used.

The process achieved considerably smaller median particle size (see Figure 2), as well as more uniformity as exemplified in narrow Azithromycin particle size distribution. The MRT process also provided better crystalline structure than the control methods, and a reduction in quantity of polymorphs that provide no pharmacological benefit.

Nanosuspensions Development Roadmap

Microfluidics recommends a three step process in development a pharmaceutical nanosuspension:

The first step is to conduct screening experiments to determine the best solvent, anti-solvent and surfactant systems, considering issues such as solubility, toxicity and compatibility for the particular application. Analysis should be conducted to select the most suitable materials and to optimize the concentrations.

The next step is to use the MRT to produce nanosuspensions. The goal at this stage is to determine the optimal processing parameters, such as feed rates of reactants, reaction chamber geometry, process pressure, super-saturation ratio, and number of passes.

The final step is to purify nanosupension, if necessary, using methods such as centrifuging, filtering, rinsing, and lyophilizing.

Next Generation Nanosuspension Processing

With the introduction of MRT, pharmaceutical and biotechnology companies now have a powerful and flexible tool to develop and ultimately manufacture difficult-to-formulate insoluble drugs. The coaxial feed system and the Microfluidizer processor reaction chamber provide precise control of critical processing parameters, including mixing ratio and reaction time, to produce nanosuspensions containing optimally- and uniformly-sized drug particles.

It has been demonstrated that MRT can create high purity nano-particles to sizes not achievable with conventional particle size reduction methods. Conventional processors cannot produce enough energy to break through nature's barrier to reduce particles smaller than the primary crystal size which varies with each material of interest. This limitation is a roadblock that prevents a growing number of critical formulations from becoming available to the marketplace.


Dinah Alobeid Account Representative Gray & Rice Public Relations One Washington Mall Boston, MA 02108 (ph) [phone] ext. 127 (fax) [phone]





Send stock manipulators to: [e-mail]-and to jail.

[MWM]

MFIC Corporation Completes New Core Management Team to Drive Global Growth Strategy
Appoints Chief Financial Officer and Vice President of Customer Success

Jun 4, 2008 8:30:00 AM
Copyright Business Wire 2008
NEWTON, Mass.--(BUSINESS WIRE)--

MFIC Corporation (OTCBB: MFIC) today announced the appointment of Brian E. LeClair, C.P.A. as Chief Financial Officer and Mary Anne North as Vice President of Customer Success. Earlier this year, the Company announced the appointment of William J. Conroy as Vice President of Operations and Engineering and the appointments of William Kober, Xavier Leroy and Kent Chu as Vice Presidents of Sales for, respectively, North and South America; Europe, the Middle East and Africa; and Asia-Pacific. All parties report directly to Michael C. Ferrara, Chief Executive Officer. In addition, the Company announced the departure of Jack Swig from his position of Vice President Corporate Development and General Counsel, effective June 30, 2008. Mr. Swig will remain available to assist MFIC on a consulting basis.

"With the addition of Brian and Mary Anne, MFIC has built the core management team needed to help our customers succeed and drive the Company's global growth strategy," said Michael C. Ferrara. "This team shares my passion to win and my belief in the significant untapped opportunity at MFIC. With their proven expertise across a broad range of functions, including strategic planning, marketing, global sales and distribution, customer service, quality control, product development and financial planning, this team is well equipped to lead MFIC to long-term sustainable growth.

"I would also like to thank Jack Swig for his fifteen years of service to MFIC. His contributions to the organization in a number of areas have been very valuable and we wish him well in his future endeavors," concluded Mr. Ferrara.

"Mike Ferrara's strengths, plans and initiatives, along with the capabilities of the new senior management team, give me great confidence in the future of MFIC and its ability to become a global leader in its field," said Jack Swig.

Brian LeClair will serve as an officer of the Company and lead MFIC's financial accounting, reporting, planning, budgeting, capital formation, contract oversight activities and IT function. Mr. LeClair will also work closely with Mr. Ferrara on investor relations activities. Dennis Riordan will continue in his role as Controller and report to Mr. LeClair.

Mr. LeClair brings more than 25 years of global senior financial executive experience for large-cap, mid-cap and small-cap companies to MFIC. Most recently, he served as CFO and CEO for SOFTPRO Group, a leading vendor providing solutions for the banking financial services industries. Mr. LeClair also has held financial executive level positions or served as a consultant for a number of companies in the software and manufacturing industry including, but not limited to, Aspen Technology, RadView Software, Ltd., Infosis Corp., and COMPAQ/MICROCOM. Mr. LeClair received in B.S. in accounting from Northeastern University and is a certified public accountant.

In a newly-created role, Mary Anne North will lead MFIC's product management, marketing and customer service departments to ensure the success of MFIC's customers across their entire experience with the Company. Ms. North's responsibilities include integrating market and product strategy around customer needs and leading all aspects of customer service, including managing MFIC's product and parts service business units.

Ms. North brings to MFIC more than 25 years of global senior executive experience with customer relationship management, product management, corporate and product marketing, sales and business development, corporate strategy and general management. Most recently, she served as President of Polaris Management, Inc., a management consulting firm that has collaborated with CEOs and their teams at more than 30 companies nationwide to accelerate growth and improve valuation. Ms. North also has held executive level positions at SolidWorks Corporation, ServiceLane, International Data Group (IDG), Desktop Data, Inc., Digital Equipment Corporation and the Chase Manhattan Bank. Ms. North has an M.B.A. from Harvard Business School and a B.A. from Stanford University.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its more than 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

[cfoofme]

I agree with this poster-if you don't hold shares and leach off common shareholders, you do not get my vote.

By: johnhcfl4144
20 May 2008, 06:40 PM EDT
Msg. 12883 of 12884
Jump to msg. #
Proxy came today...how I voted..

I went with the recommendations with one exception. I withheld approval for the election of James Little.

As I have pointed out many times, James Little has been on the Board of Directors since December, 1995. During that time, the company has lost money 7 out of the 11 years, lost over $1.12 per share over that time frame, the share price has gone from $2.50 in 1996 to $1.10 today. The purchasing power of $2.50 in 1996 would need about a $4 share price today to keep even with inflation. After 11 years, the company has a market capitalization today less than what is was in 1996. This is shameful.

During the time frame, James Little has accepted well over $100,000 in compensation from MFIC. He has not purchased a single share of MFIC stock in the open market...not one..he has exercised options at $.41 and $.51 when the share price was well in excess of his purchase price. The Chairman of Board of MFIC has not purchase a single share of stock in the open market.

In my opinion, his performance and commitment to the shareholders of this company and willingness to share the risks of ownership do not merit reelection

[cfoofme]

MFIC Corporation Announces First Quarter 2008 Financial Results
7:21a ET May 13, 2008 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today reported financial results for the quarter ended March 31, 2008. MFIC is an industry-leader in high-shear liquid processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

MFIC reported that for the first quarter ended March 31, 2008, the Company recorded negative EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of $410,000 or ($.04) per basic and diluted share. This compares to the first quarter of 2007, where the Company reported negative EBITDA of $389,000 or ($.04) per basic and diluted share. For the first quarter 2008, the Company posted revenues of approximately $3.5 million compared to $2.8 million during the first quarter of 2007, representing an increase of almost 26% and marking the highest first-quarter revenue in the history of the Company's Microfluidics Division. For the first quarter ended March 31, 2008, the Company posted a net loss of $445,000 or $.04 per basic and diluted share, as compared with a net loss of $417,000 or $.04 per basic and diluted share, for the quarter ended March 31, 2007. Of note, the first quarter of 2008 included a charge of $130,000 associated with the retirement of Robert Bruno, President and Chief Operating Officer, and the departure of Thomas Hoarty, Vice President of Marketing and Sales, and $110,000 in charges primarily associated with the strategic planning process and also related to the recruitment of the new leadership team.

The Company's order backlog at March 31, 2008 was $4.1 million compared to backlog of $2.9 million as of March 31, 2007. The first quarter 2008 backlog is the highest first-quarter backlog in the history of the Company's Microfluidics Division.

"Over the last quarter, MFIC established major elements of the foundation of our global growth strategy," said Michael C. Ferrara, Chief Executive Officer. "Consistent with our plan to invest in the Company in 2008, we made important additions to our senior management team hiring individuals with exceptional experience in global sales and distribution and operations and quality. We undertook a number of initiatives to build upon the overall quality of our products while also lowering our production costs and lead times. We are actively expanding our distribution channels in North America, Asia and Europe and we recently presented our global growth strategy to our worldwide sales representatives and distributors."

MFIC has recently accomplished a number of significant milestones:

-- Continued impressive sales of the M-110P Microfluidizer(R) Processor, an innovative benchtop "Plug and Play" machine. As of March 31, 2008, the Company has shipped seven M-110P units and there are 24 units in backlog.

-- Restructured the sales organization, including the hiring of a new global sales leadership team with extensive experience in global sales, marketing and distribution. The new leadership team recently coordinated and held sales meetings for both North America and Asia sales representatives and distributors and is working with individual representatives and distributors to establish sales goals for the remainder of the year.

-- Launched major quality initiative with the appointment of William Conroy as Vice President of Operations and Engineering. Since assuming the position in March, Mr. Conroy has established and implemented operational performance metrics for the Company's product development and manufacturing departments and begun to address quality improvement and cost reduction opportunities.

-- Completed a customer- and employee-focused renovation of MFIC headquarters, including more efficient and productive manufacturing space utilization and the creation of meeting space available for use by global customers and suppliers during their visits to MFIC.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

EBITDA and Non-GAAP Measures

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies.

One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.

Forward-Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to achieve, maintain and/or increase growth in revenue and/or market share, to achieve, maintain and/or increase operating profitability and/or to achieve, maintain and/or increase net operating profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of our Microfluidizer materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the timing of orders will significantly affect quarter to quarter revenues and resulting net income results for a particular quarter, which may cause increased volatility in our stock price, (iii) whether we will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to our ability to maintain compliance with the covenants and terms of our loan agreement with our senior lender, (iv) whether our Microfluidics Reaction Technology will be adopted by customers as a means of producing innovative materials in large quantities, (v) whether we are able to deploy prototype Microfluidics Reaction Technology systems for nanoparticle production and then manufacture and introduce commercial production Microfluidics Reaction Technology equipment, and (vi) whether we will achieve a greater proportion of our sales in the future through the sale of advanced processor production systems. --Financial Charts Follow-

MFIC CORPORATION Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three Months Ended March 31, -------------------------- 2008 2007 ------------- ------------ Revenues $ 3,522 $ 2,801 Cost of sales 1,609 1,194 ------------- ------------ Gross profit 1,913 1,607 ------------- ------------ Operating expenses: Research and development 491 536 Selling 932 824 General and administrative 941 677 ------------- ------------ Total Operating expenses 2,364 2,037 ------------- ------------ Loss from operations (451) (430) Interest expense (5) (8) Interest income 11 21 ------------- ------------ Net loss $ (445) $ (417) ============= ============ Net loss per common share: Basic $ (0.04) $ (0.04) Diluted $ (0.04) $ (0.04) Weighted average number of common and common equivalent shares outstanding: Basic 10,260,482 10,123,084 Diluted 10,260,482 10,123,084
U.S. GAAP to Non-GAAP Measure Reconciliations and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (in thousands, except share and per share amounts) Quarter Ended March 31, --------------------- 2008 2007 ---------- ---------- Net loss $(445) $(417) Net interest income (6) (13) ---------- ---------- Depreciation and amortization 41 41 ---------- ---------- EBITDA (Non-GAAP Measure) $(410) $(389) ========== ========== Weighted average number of common and common equivalent shares outstanding: Basic 10,260,482 10,123,084 Diluted 10,260,482 10,123,084 EBITDA per common share (Non-GAAP Measure): Basic $(.04) $(.04) Diluted $(.04) $(.04)
Summary Consolidated Unaudited Balance Sheet Information (Unaudited - in thousands) ---------------------------------------------------------------------- March 31, December 31, 2008 2007 Current Assets(a) $6,475 $5,972 Current Liabilities $2,728 $1,590 Total Stockholders' Equity $4,387 $4,767

SOURCE: MFIC Corporation

MFIC Corporation Jack M. Swig, 617-969-5452 [e-mail] or MacDougall Biomedical Communications Sarah Cavanaugh, 781-235-3060 [e-mail]

[cfoofme]

Microfluidics Carbon Nanotubes for consideration for June focus



NEWTON, Mass., April 28, 2008 – Microfluidics, a wholly owned subsidiary of MFIC Corporation, announces methods for processing bulk carbon nanotubes. Microfluidics has devised a methodology to process, deagglomerate, purify and stabilize these processed nanotubes so they can be used in an optimal manner, thus achieving enhanced functionality and performance.





The company has identified and demonstrated numerous operational protocols utilizing its Microfluidizer® processor systems to prepare these bulk nanotubes for their ultimate specific uses. These applications capitalize on the unique mechanical, electrical and thermal properties of carbon nanotubes, and require dispersion of the nanotubes in liquid media and independent length reduction of the carbon nanotubes.

Carbon nanotubes are noted for their tubular shape, extremely small diameter with respect to length, and exceptional physical, mechanical and electrical properties. When prepared in diameters in the 10-50 nanometer range, the unique characteristics of strength, conductivity and quantum behavior become highly desirable and are thus incorporated into a multitude of commercial products.

Microfluidizer® processors are ideal for conditioning carbon nanotubes (and nanomaterials in general) for applications that include high tensile strength polymers, fabric treatments, lubricants, medical therapeutics, computer memory and chips, electronic devices, medical diagnostic biolabels, and photovoltaic cell components.

About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.
# # #


CONTACT: Katie DePorter
Gray & Rice Public Relations
617-367-0100 ext. 121
[e-mail]

[cfoofme]

Microfluidics Announces Retirement of Robert Bruno



Newton, Mass., April 16, 2008 - Microfluidics, a wholly owned subsidiary of MFIC Corporation, has announced that Robert Bruno will retire from his position as President and Chief Operating Officer effective, June 30, 2008.




Mr. Bruno, a licensed Professional Engineer and a graduate of Northeastern University with an advanced degree in Mechanical Engineering, joined Microfluidics in March of 1996 as Vice President of Sales and Marketing. He was promoted to President and Chief Operating Officer of both Microfluidics and MFIC in March 2001.


Over the last twelve years, Mr. Bruno worked to grow the Company's business through product innovation, the expansion of a global sales network and the establishment of highly effective engineering and manufacturing organizations. Mr. Bruno spearheaded the development of the Company's MicrofluidizerR processor model M-700 standardized "BioPharm" product line, which played a critical role in Microfluidics' rapid growth in the biopharmaceutical markets.


More recently, Mr. Bruno led the design and development of Microfluidics' highly successful new product, the M-110P laboratory Microfluidizer processor. During his tenure, Mr. Bruno also oversaw the introduction of several key differentiating product features that established Microfluidics as a world leader in biopharmaceutical high shear fluid processing.


"It has been a pleasure working with Bob as he has made significant contributions to the development of our business, our product portfolio and the overall organization," stated Michael C. Ferrara, Chief Executive Officer of MFIC. "We appreciate his dedication over the years and wish him all the best in his retirement."

"I'm proud to have played a role in the growth of Microfluidics and to have been associated with such a great team of dedicated employees," said Mr. Bruno. "While I am happy to be retiring, I am highly confident in the future of Microfluidics and look forward to monitoring its continued success."


About Microfluidics

Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of MicrofluidizerR high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com www.microfluidicsc orp.com> , email [e-mail] or contact Microfluidics at 800.370.5452

[cfoofme]

Nobile at Taglich upgrades MFIC.
Baton
From the report:
Key investment considerations:
We are upgrading our rating for shares of MFIC Corporation (OTC BB: MFIC) to Speculative Buy from Neutral and setting a twelve-month price target of $2.00. We believe the Company’s backlog supports near-term growth while new leadership should drive long-term growth.
On March 12, 2008, MFIC announced that fourth quarter 2007 revenues decreased 14% to $4.3 million from $5.0 million in the same period in fiscal 2006. The net loss was $0.1 million or $(0.01) per share versus net income of $1.0 million or $0.10 per diluted share.
Looking at the Company’s results over the past few years, backlog has proven to be a good indicator of what level of revenues to expect for an upcoming quarter. The Company’s order backlog at December 31, 2007 was a healthy $4.4 million and grew to approximately $4.7 million as of March 7, 2008.
We met with MFIC’s CEO Mike Ferrara in late January and walked away with the impression that MFIC had the right man in place to turn the Company around. On the fourth quarter conference call, Ferrara confirmed his strategy for the Company and said that 2008 would be a year of change and of wise investments for MFIC. Ferrara was previously CEO at X-Rite Inc. where he was able to achieve record-level revenues and earnings.
For fiscal 2008, we estimate MFIC will generate revenue of $18.0 million and report net income of $1.3 million or $0.12 per diluted share. Previous estimates called for fiscal 2008 revenue of $13.1 million and a net loss of $1.0 million or $(0.09) per share.
http://www.taglichbrothers.com/equityuniverse/companies/mficcorp/mficcorp.asp

[cfoofme]

Thanks to this poster:

By: johnhcfl4144
09 Apr 2008, 06:54 PM EDT
Msg. 12813 of 12813
Jump to msg. #
Conference Call Notes...Introductory comments

I listened to the conference call again with a notepad and I am sharing these notes with our board readers. I would urge you to do the same thing...there was a lot of ground covered.

Mike Ferrara our new CEO shared some his background including becoming CEO of a broadly similar company named XRite which had a series of exemplary growth years under his leadership.

Comments..I am excited about the technology..we are in the process of developing and executing strategies..we will get better everyday..we will become customer-focused..that is necessary

first and foremost...SELL MORE ..develop a sales strategy..the first installment of strategy is in place...we have put in place a new sales leadership team..Mike spoke extensively about Mizuho and Japan which I outlined in an earlier post..Mizuho as recently as 2-3 years ago generated over $2million in a single year..

Mike spoke about the potential of restoring the relationship, building on the 200-250 unit installed base in Japan..expanding the sales coverage there through Mizuho selling the whole product line or adding additional reps who will..He spoke of the great market potential in China, Korea (where there is a decent base), Australia, Singapore and India.

Reps have been hired for Asia and Europe..press release has been commented by others on this board..this is a seasoned team..experienced in the geographic areas to which they have been assigned..and if I was a CEO of a new company, I would seek to hire winners from my old firm if the skillset is appropriate..

Hiring a new VP of Operations who is now in place.

Developing a product design team which would include the people who would service the machines and customers who would use them..

That he has implemented a high single-digit price increase..which shows confidence in the value of the product line..and with the decline in the value of the dollar vis-a-vis the yen and the Euro will probably allow another increase yet this year.

Mike was extremely complimentary of the efforts of Bob Bruno in developing and pricing the new 1100 lab unit..

Several references to the completion of 3 year strategic plan around Labor Day..

And most important to me...his enthusiasm expressed in "We have an Order" about a new piece of business from Mizuho

By way of disclosure, I am a long-term shareholder and continue to add to my position at good buying opportunities. I have no recommendation as to what anyone else should do..these posts are a way to clarify my own thinking.

Based on this call alone, we have more ways of evaluating this investment than we have ever had presented to us before. Mike Ferrara is accountable.

[cfoofme]

April 07, 2008 01:37 PM Eastern Daylight Time PermalinkTo save a permanent link to this news, right-click the dateline (Ctl-click on a Mac) to copy the link.


MFIC Corporation Appoints New Microfluidics’ Sales Leadership Team
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC) today announced that its wholly-owned operating subsidiary, Microfluidics Corporation, has appointed William Kober, Xavier Leroy and Kent Chu as Vice Presidents of Sales to execute on the Company’s global growth strategy and to lead key regional geographic sales organizations consisting of sales managers, distributors and independent manufacturers representatives. Mr. Kober will oversee North and South America; Mr. Leroy will oversee Europe, the Middle East and Africa and Mr. Chu will oversee Asia-Pacific. All parties will report directly to Michael C. Ferrara, Chief Executive Officer.

These newly created geographic roles will be responsible for identifying and defining existing and new growth and partnering opportunities. The VPs will also be charged with developing enhanced sales and distribution channels by region and market vertical segments and building relationships with key customers and accounts.

“The creation of this team is a critical step in improving our global sales, service and marketing business model,” said Michael C. Ferrara, CEO of MFIC Corporation. “These three individuals have exceptional, proven experience in building global sales, marketing and distribution channels and will not only increase our overall sales coverage, but will also make our existing coverage more effective. I look forward to working with the team as we position MFIC for long-term, sustainable global growth.”

In addition to the appointments to the sales executive team, there will also be two departures. As previously announced in March of 2008, Robert Bruno will, as planned, retire from his position as President and Chief Operating Officer, effective June 30, 2008. In addition, Thomas Hoarty, Vice President of Marketing and Sales, will be leaving the Company, effective April 30, 2008 to pursue other opportunities.

Mr. Kober brings more than twenty-five years of scientific instrumentation sales and marketing experience to Microfluidics. Most recently, he served as Vice President of Sales for the Americas at X-Rite, Inc. where he increased revenue an average of 8% year-over-year in his geographic territories. Mr. Kober also held senior level sales positions at Color & Appearance Technologies, Inc. and DataColor International.

Mr. Leroy brings more than fifteen years of technological business to business sales and marketing experience to Microfluidics. Most recently, he served as Managing Director of Sales for Southern Europe and Northern Africa and General Manager of Sales for France, Italy and Spain at X-Rite, Inc. where he grew the business 120% over a five-year period across his geographic territories. Mr. Leroy also held senior level sales positions of increasing responsibility at Vannier-Photelec SA.

Mr. Chu brings more than twenty years of sales, product and people management experience in both the domestic and international high technology instrument markets to Microfluidics. Most recently, he served as Vice President of Sales for Asia-Pacific at X-Rite, Inc. where he averaged double-digit sales growth annually for a ten-year period. Prior to this, Mr. Chu held increasing senior sales and marketing positions at X-Rite, Inc., ACS Inc. and CPC International.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its more than 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to our plan to achieve, maintain and/or increase growth in revenue and/or market share, to achieve, maintain, and/or increase operating profitability, and/or to achieve, maintain, and/or increase net operating profitability. Such statements are based on our current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by us to differ materially from those described in the forward-looking statements. We caution investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to, the following risks and uncertainties: (i) whether the performance advantages of our Microfluidizer materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the timing of orders will significantly affect quarter to quarter revenues and resulting net income results for a particular quarter, which may cause increased volatility in our stock price, (iii) whether we will have access to sufficient working capital through continued and improving cash flow from sales and ongoing borrowing availability, the latter being subject to our ability to maintain compliance with the covenants and terms of our loan agreement with our senior lender, (iv) whether our Microfluidics Reaction Technology will be adopted by customers as a means of producing innovative materials in large quantities, (v) whether we are able to deploy prototype Microfluidics Reaction Technology systems for nanoparticle production and then manufacture and introduce commercial production Microfluidics Reaction Technology equipment, and (vi) whether we will achieve a greater proportion of our sales in the future through the sale of advanced processor production systems.

[cfoofme]

MFIC Corporation Appoints Vice President of Operations and Engineering
5:08p ET March 25, 2008 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today announced the appointment of William J. Conroy as Vice President of Operations and Engineering. In this position, Mr. Conroy will have responsibility for the global operations of the Company's Microfluidics equipment business, including product design and engineering, production, quality assurance and quality control, and purchasing. In direct support of MFIC's quality initiative, Mr. Conroy will also assume responsibility for overall systems quality and reliability. Mr. Conroy will report directly to Michael C. Ferrara, Chief Executive Officer.

"Bill is an important addition to the MFIC management team and we believe that the Company and our customers will greatly benefit from his extensive experience," said Michael C. Ferrara. "Bill's proven ability to create highly functioning, quality-driven operating units and his strong innovation and leadership skills will play a critical role in MFIC's global growth strategy."

"I'm pleased to be joining MFIC at such an important time in the Company's history," said William J. Conroy. "I believe MFIC has substantial opportunity for global growth and I look forward to working with the team to build an operations organization that is second to none in terms of innovation, quality and customer focus."

Mr. Conroy brings more than twenty-five years of high-tech product management, quality control and operations experience to MFIC. Most recently, he served as Senior Vice President of Production and Operations at RemoteReality Corporation, which designs and manufactures products for the military/defense and security business sectors. Mr. Conroy has also held senior level operations, manufacturing and quality control positions at Northrop Grumman (formerly Fibersense Technology Corporation), Karl Storz Endovision, Circon ACMI and Kohler Company.

[MWM]

MFIC Corporation Announces Fourth Quarter and Year-end 2007 Financial Results
Company reports second highest revenue quarter since 2001
Mar 12, 2008 7:03:00 AM
Copyright Business Wire 2008
View Additional ProfilesNEWTON, Mass.--(BUSINESS WIRE)--

MFIC Corporation (OTCBB: MFIC) today reported financial results for the quarter and year-ended December 31, 2007. MFIC is an industry-leader in high-shear liquid processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

MFIC reported that for the fourth quarter ended December 31, 2007, the Company achieved $287,000 or $0.03 per basic and diluted share EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization). This compares to the record fourth quarter of 2006-the highest revenue quarter in MFIC's history-where the Company reported $828,000 or $0.08 per basic and diluted share EBITDA. For the fourth quarter 2007, the Company posted revenues of approximately $4.32 million compared to $5.04 million during the fourth quarter of 2006, representing a decrease of approximately 14%. For the fourth quarter ended December 31, 2007, the Company posted a net loss of $124,000 or $0.01 per basic and diluted share, as compared with net income of $1.02 million or $0.10 per basic and diluted share, for the quarter ended December 31, 2006. Of note, the fourth quarter 2007 results included an income tax provision of $369,000, ($0.04 per share), while the fourth quarter of 2006 included an income tax benefit of $228,000 ($0.02 per share).

For the twelve-month period ended December 31, 2007, MFIC reported negative EBITDA of $1.01 million or $0.10 per basic and diluted share. This compares to the year ended 2006 where the Company reported EBITDA of $1.38 million or $0.14 and $0.13 per basic and diluted share, respectively. MFIC also reported revenues for year ended 2007 of approximately $12.99 million compared to $15.65 million for the year ended December 31, 2006, representing a decrease of 17%. For the year ended December 31, 2007, the Company reported a net loss of $1.5 million or $0.15 per basic and diluted share compared to a net income of $1.3 million or $0.13 and $0.12 per basic and diluted share respectively for same period in 2006.

"As the new CEO of MFIC, my focus in 2008 is to build a solid foundation for sustainable growth," said Michael C. Ferrara. "We are implementing a plan focused on technological innovation, expanded senior leadership and a restructured sales and marketing model. The plan identifies a number of strategic investments to drive both top line and bottom line improvement and focus MFIC on quality and the customer."

The Company's order backlog at December 31, 2007 was $4.39 million compared to backlog of $3.01 million as of December 31, 2006. Backlog grew to approximately $4.71 million as of March 7, 2008, compared to $3.57 million as of March 23, 2007.Backlog represents orders in hand that typically take between one and six months to deliver.

During 2007, MFIC accomplished a number of significant milestones:

-- Introduced the M-110P Microfluidizer(R) processor, an
innovative benchtop "Plug and Play" machine. Orders for twelve
machines were in MFIC's backlog by year-end and have increased
to twenty four as of March 7, 2008.

-- Presented data supporting the significance of Microfluidics
Reaction Technology during a poster presentation at the Nano
Science and Technology Institute Nanotech 2007 Conference.

-- Announced that the Company's subsidiary, Microfluidics, was
named a technology category winner in the third annual
Nanotech Briefs(R) Nano 50(TM) Awards for its revolutionary
new Microfluidics Reaction Technology-a next-generation
approach in the production of nanosuspensions to help
pharmaceutical and biotechnology companies develop and
ultimately manufacture difficult to formulate drugs.

-- Opened the Microfluidics Technology Center, which serves as an
innovation hub for the Company's highly-specialized research
team.

About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

[cfoofme]

Anyone else heard about cc?


By: johnhcfl4144
12 Feb 2008, 06:18 PM EST
Msg. 12706 of 12708
Jump to msg. #
pushing 7% of shares

Mr. Daly has continued to add to his position. The shares are now forming a long, stable base as the shares get consolidated in fewer hands. Judging by the postings, some people who had significant holdings have moved out of this stock because their posts no longer appear. So we have had a turnover in the shareholders that has resulted in those shares moving to fewer, and in Daly's case especially, much stronger hands. I have added to my position..adding about 30%..on buying opportunities as they have arisen, during the past year. Think also of the purchases of shares by the directors in the open market (with the exception of Jim Little who has never purchased a single share in the open market, despite being on the Board since 1996 and having collected well over $100,000 from the company in stipends) and the management team, and other long-term posters on this board, consolidated holdings have intensified. These are extraordinary events.

If you have read my earlier postings, I think a good quarter, and a good sales backlog for the current quarter that the conference call is being held in, will accelerate the accumulation phase of the stock cycle. It is my understanding that the company will try to announce around March 11th, with a conference call on the 12th. If we have a decent q4, and a nice backlog in q1, there is a very good chance of this process occuring.

Think about this..from accumulation to markup phase..there are no shares for an operator to accumulate without pushing the shares.. this stock is now in pretty firm hands...at the conference call, Mike will now have been on board for 4.5 months or so...and given his past track record...my expectations is that he will have an executable plan of action..a solid q2, which we will have a feel for in the q1 conference call in early May...and I think we can get the share price to a level which will lead to a higher market listing..

Then, better liquidity in the stock, a developing company in a once-hot, now dead area called nanotechnology, will see that space come back into favor and lead to major advances in 2009..

So if the company executes, and Lord knows that they never have, the future for the share price is very bright

[cfoofme]

Press Release Date: January 10, 2008

Microfluidics to Showcase M-110p Microfluidizer® Processor at Interphex 2008

For More Information, Visit Booth #1618

Newton, Mass. - Microfluidics will showcase its portable M-110P Microfluidizer® processor, a bench top lab machine that requires no compressed air or cooling water for hydraulics, at the Interphex 2008 Conference and Exhibition from March 26-28 in Philadelphia, PA. Designed to operate reliably, quietly and efficiently at up to 30,000 psi process pressure, the portable M-110P only requires a standard 20 amp, single phase "household" electrical outlet and can easily be incorporated into any laboratory setting.

Utilizing Microfluidics' fixed geometry diamond interaction chamber technology and ceramic plunger, the M-110P easily enables the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption with the fewest number of passes. Additionally, the M-110P allows flow rates between 110-155 ml/minute depending on process pressure, which is a higher flow rate than any comparable, competitive product. This flow rate enables the efficient processing of pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P machine are guaranteed to be scaleable to pilot and/or production volumes.

About Microfluidics Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.
Company Information:
Microfluidics, Division MFIC Corp.
30 Ossipee Rd.
Newton, MA 02464 9101
USA
Phone:
FAX: [phone]
http://www.microfluidicscorp

[cfoofme]

Shareholder letter from website:

Dear Shareholders,

Happy New Year!

During my first six weeks as CEO, I discussed with some of you your initial motivation in taking a position in MFIC. Like many of you, I too was drawn to MFIC because I believe the Company has a real opportunity for substantial global growth. With the implementation of aggressive global strategies, I feel we can capitalize on the Company's innovative products and technologies for our customers, employees and shareholders.


I have begun working on a strategic plan with Company management, customers and influential global experts. I look forward to sharing some of the elements of this plan with you later in 2008 and during a shareholder conference call that we intend to schedule in March to coincide with the reporting of our fourth quarter and year-end ’07 financial results.

My focus in 2008 will be on growth and making investments in some key areas:

• Domestic sales coverage

• Transition from an export to global business in Asia Pacific and Europe

• Marketing

• Operations and quality

• New business initiatives, including Microfluidics Reaction Technology and others

• Culture – Passionately focus all energy and decision making around the customer, innovation and growing the enterprise

Thank you for you continued support. I look forward to communicating MFIC's progress throughout 2008.

Sincerely,

Michael C. Ferrara

CEO

[MWM]

Everyone in the compnay bought 7500 worth of stock options today...

2:54 PM Form 4 MFIC CORP For: Jan 02 Filed by: WALTERS ERIC G (10K)
2:52 PM Form 4 MFIC CORP For: Jan 02 Filed by: LITTLE JAMES N (10K)
2:49 PM Form 4 MFIC CORP For: Jan 02 Filed by: ROY LEO PIERRE (10K)
2:46 PM Form 4 MFIC CORP For: Jan 02 Filed by: UVEGES GEORGE (10K)

[MWM]

$1.16 not bad!

[MWM]

Tax loss season is over this should rebound nicely!

[MWM]

and the price is right...

[bonedaddy77]

I remember looking at it earlier in the year...liked what I saw.

[MWM]

MFIC Corporation Appoints Michael C. Ferrara Chief Executive Officer
MFIC Corporation (OTCBB: MFIC) today announced that Michael C. Ferrara has been appointed Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Ferrara was most recently President and CEO of X-Rite where he led the corporation’s reemergence as the global leader of its industry. X-Rite, a $352 million market capitalization NASDAQ-traded company (XRIT), is the global leader in color science and technology, developing, manufacturing and marketing innovative color management solutions for industrial, commercial and retail applications. Under Mr. Ferrara’s leadership, X-Rite grew organically to achieve record-level revenues and earnings through the introduction of 61 new products in five years, distribution gains and industry-changing merger and acquisitions in the color technology space-including the acquisition of Amazys Holding AG, which was awarded in 2006 “The International Deal of the Year” by The M&A Advisor™. Mr. Ferrara also has extensive experience in building marketing and distribution channels with strategic partners in markets throughout the world, including Asia-Pacific and EMEA—areas of considerable focus for MFIC moving forward.

“Mike’s relationships on Wall Street, his strategic vision and his proven ability to lead companies to success will be important in unlocking the value of MFIC as we continue to position the Company for long-term sustainable growth,” said James N. Little, Ph.D., Acting Chairman of the Board of Directors. “The Board believes Mike’s experience is an excellent fit for the breadth of opportunity at MFIC and we look forward to working with him to facilitate MFIC’s growth and success under his leadership.”

“MFIC has put in place a foundation to support the growth-potential of the Company,” said Michael C. Ferrara, Chief Executive Officer. “I look forward to working with the team around the world to capitalize on our innovative technologies and products such that the potential of MFIC is realized for all stakeholders and shareholder value is consistently improved.”

Michael Ferrara was previously Chief Executive Officer and President of X-Rite Incorporated. Prior to X-Rite, Mr. Ferrara was CEO of Marine Optical Group, CEO of N.I. World Trade, a trading subsidiary of National Intergroup (formerly National Steel) and held positions of increasing seniority over an 18-year period at Westinghouse Electric Corporation. Mr. Ferrara has a B.S in electrical engineering from Villanova University and completed the Program for Management Development (PMD) at Harvard Business School.

[MWM]

I have a friend who really likes this stock, has said for years their tech is extremly impressive...
Pretty obvious buy under $1 here, new CEO might get this company on track for 2008...

[bonedaddy77]

I was just looking at the chart..wow..nice add.

[MWM]

Added .95 here...

[cfoofme]

News article:

http://news.thomasnet.com/fullstory/537166

[MWM]

Making a nice comeback here! Didn't think it was going under $1...

[cfoofme]

Insiders buying = good news in future?

http://www.nasdaq.com/asp/quotes_sec.asp?page=filings&symbol=mfic&selected=mfic&rpage=sec&

[cfoofme]

Interesting positive find:

By: sixersadvantcom
21 Nov 2007, 09:00 PM EST
Msg. 12657 of 12657
Jump to msg. #
Things are looking up for our little company. Director George Uveges purchased 20,000 shares on 11/19 & 11/20 for prices $1.10 to $1.14.
George has an impressive background. This is from the last 14-A filing.

"GEORGE UVEGES has served as a director of the Company since November 2005. Mr. Uveges is the founder and principal in the Tallwood Group, an angel investing firm that provides financial and management advisory services in addition to investment capital. Mr. Uveges has been a member of the adjunct faculty at Newbury College since 2006. From 2001 to 2004, Mr. Uveges served as the President and Chief Executive Officer of TranXenoGen, Inc., a development-stage, publicly-held biotech company focused on developing new methods for manufacturing therapeutic proteins and a portfolio of products, including generics, a cancer treatment and antibodies. He was also a director of that company from 2001 to 2005. Prior to that, Mr. Uveges served as Chief Financial Officer at a number of companies and also practiced as a certified public accountant. Mr. Uveges is a member of the Board of Directors of Harvard Bioscience, Inc., a publicly held developer, manufacturer and marketer of products used in life science research, where he also serves on the audit committee. Mr. Uveges is also a member of the Board of Directors of Operation ABLE, a non-profit corporation. Mr. Uveges is the Chairman of the Company’s Nominating and Corporate Governance Committee, is a member of the Company’s Audit and Compensation Committees and is a “financial expert” on the Audit Committee."

Also, Robert Bruno exercised options for 39,750 shares and apparently held the shares.

[cfoofme]

MFIC Corporation Appoints Michael C. Ferrara Chief Executive Officer
9:03a ET November 14, 2007 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today announced that Michael C. Ferrara has been appointed Chief Executive Officer and a member of the Company's Board of Directors. Mr. Ferrara was most recently President and CEO of X-Rite where he led the corporation's reemergence as the global leader of its industry. X-Rite, a $352 million market capitalization NASDAQ-traded company (XRIT), is the global leader in color science and technology, developing, manufacturing and marketing innovative color management solutions for industrial, commercial and retail applications. Under Mr. Ferrara's leadership, X-Rite grew organically to achieve record-level revenues and earnings through the introduction of 61 new products in five years, distribution gains and industry-changing merger and acquisitions in the color technology space-including the acquisition of Amazys Holding AG, which was awarded in 2006 "The International Deal of the Year" by The M&A Advisor(TM). Mr. Ferrara also has extensive experience in building marketing and distribution channels with strategic partners in markets throughout the world, including Asia-Pacific and EMEA--areas of considerable focus for MFIC moving forward.

"Mike's relationships on Wall Street, his strategic vision and his proven ability to lead companies to success will be important in unlocking the value of MFIC as we continue to position the Company for long-term sustainable growth," said James N. Little, Ph.D., Acting Chairman of the Board of Directors. "The Board believes Mike's experience is an excellent fit for the breadth of opportunity at MFIC and we look forward to working with him to facilitate MFIC's growth and success under his leadership."

"MFIC has put in place a foundation to support the growth-potential of the Company," said Michael C. Ferrara, Chief Executive Officer. "I look forward to working with the team around the world to capitalize on our innovative technologies and products such that the potential of MFIC is realized for all stakeholders and shareholder value is consistently improved."

Michael Ferrara was previously Chief Executive Officer and President of X-Rite Incorporated. Prior to X-Rite, Mr. Ferrara was CEO of Marine Optical Group, CEO of N.I. World Trade, a trading subsidiary of National Intergroup (formerly National Steel) and held positions of increasing seniority over an 18-year period at Westinghouse Electric Corporation. Mr. Ferrara has a B.S in electrical engineering from Villanova University and completed the Program for Management Development (PMD) at Harvard Business School

[cfoofme]

MFIC Corporation Announces Third Quarter Financial Results
4:35p ET November 13, 2007 (Business Wire)
MFIC Corporation (OTCBB: MFIC) today reported financial results for the quarter ended September 30, 2007. MFIC is an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

MFIC reported that for the third quarter ended September 30, 2007, the Company posted revenues of approximately $2.3 million compared to $3.6 million during the third quarter of 2006, representing a decrease of approximately 36%. Third quarter sales were impacted by decreases in all geographic markets.

In North America, lower sales were primarily driven by (i) a customer's decision to request additional enhancements to a major system order that delayed delivery and revenue recognition until a later date; and (ii) an expected decrease in spare part sales as a result of a previously disclosed decision by a major customer to reschedule delivery due to a change in their production schedule.

Lower foreign sales were driven primarily by a decrease in the sale of machines to significant customers, particularly in Asia. This includes a continued decrease in sales made by MFIC's Japanese distributor. The distributor has not been aggressively selling MFIC products due to its technical issue with a major installation. MFIC believes the recurring problems with these machines are the direct result of the maintenance of the machines by the distributor and the customer. MFIC has assigned a dedicated technical team which has worked very closely with the distributor's service group and the distributor's service group has since taken steps to address the issues. In addition, Robert P. Bruno, President and Chief Operating Officer of MFIC, traveled to Japan in September to meet with the distributor's management team. MFIC continues to work on this important issue.

"We are certainly disappointed with our third-quarter results," said Robert P. Bruno, President and Chief Operating Officer of MFIC Corporation. "However, while our sales in Japan continue to fall short of previous quarters, we believe we have a good foundation in Asia, specifically in China and Korea where we are encouraged by the demand we have seen in these markets over time. We are also pleased with the initial sales response to the M-110P, introduced in late September of 2007. We have received orders for the first seven production units and have issued numerous additional quotations. We expect to begin delivering units late this year or in early 2008. In addition, we continue to see strong sales of our biopharmaceutical production machines to some of our largest customers."

"While this has been a difficult quarter for MFIC, the Company is financially sound, having cash and receivables that are well in excess of current liabilities," said James N. Little, Ph.D., Acting Chairman of MFIC Corporation. "These lumpy quarters, while taken very seriously, are normal in the capital goods business. We continue to focus on building long-term sustainable growth and our backlog has grown substantially since the quarter's end."

For the third quarter ended September 30, 2007, the Company posted a net loss of $859,000, or $.08 per diluted share, as compared with net income of $85,000, or $0.01 per diluted share, for the quarter ended September 30, 2006. The third quarter 2007 results included no income tax provision while the third quarter of 2006 included an income tax expense of $57,000.

Operating expenses increased by $200,000, or 10.5% to $2.1 million for the quarter ended September 30, 2007 from $1.9 million for the quarter ended September 30, 2006. The increase was primarily due to increases in sales and marketing expenses, administrative costs associated with the departure of the Company's prior CEO and costs associated to fill the vacancy and a planned increase in public relations.

The Company's order backlog at September 30, 2007 was $3.8 million compared to backlogs of $4.9 million and $3.0 million on September 30, 2006 and June 30, 2007, respectively. Backlog grew to approximately $4.9 million as of November 9, 2007, including a letter of intent to purchase a significant production system from a major pharmaceutical customer. Backlog represents orders in hand that typically take between one and six months to deliver, with the exception of a spare parts supply order scheduled to ship over a longer period.

For the nine-month period ended September 30, 2007, revenues decreased by $1.9 million or 18.0%, to $8.7 million, and the Company reported a net loss of $0.14 per diluted share, as compared with $10.6 million in revenues, and a net profit of $0.02 per diluted share, for the first nine months of 2006.

During the third quarter 2007 MFIC Corporation accomplished significant milestones:

-- Launched the M-110P Microfluidizer(R) processor, an innovative benchtop "Plug and Play" machine that provides a solution for customers lacking compressed air required to operate MFIC's existing air operated laboratory equipment

-- Announced that the Company's subsidiary, Microfluidics, was named a technology category winner in the third annual Nanotech Briefs(R) Nano 50(TM) Awards for its revolutionary new Microfluidics Reaction Technology (MRT)_a next-generation approach in the production of nanosuspensions to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs

-- Continued to make solid progress in the search for a CEO candidate

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.

Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three For The Nine Months Ended Months Ended September 30, September 30, ----------------------------------- 2007 2006 2007 2006 -------- -------- -------- -------- Revenues $ 2,311 $ 3,553 $ 8,670 $10,614 Cost of sales 1,118 1,558 3,765 4,806 -------- -------- -------- -------- Gross profit 1,193 1,995 4,905 5,808 -------- -------- -------- -------- Operating expenses: Research and development 436 424 1,411 1,274 Selling 840 723 2,649 2,081 General and administrative 784 707 2,267 2,030 -------- -------- -------- -------- 2,060 1,854 6,327 5,385 -------- -------- -------- -------- (Loss) income from operations (867) 141 (1,422) 423 Interest expense (7) (9) (15) (29) Interest income 15 10 53 31 -------- -------- -------- -------- (Loss) income before income tax provision (859) 142 (1,384) 425 Income tax provision - 57 - 170 -------- -------- -------- -------- Net (loss) income $ (859) $ 85 $(1,384) $ 255 ======== ======== ======== ======== Net (loss) income per common share: Basic $ (0.08) $ 0.01 $ (0.14) $ 0.03 Diluted $ (0.08) $ 0.01 $ (0.14) $ 0.02 Weighted average number of common and common equivalent shares outstanding: Basic 10,203 10,045 10,169 9,991 Diluted 10,203 10,561 10,169 10,517
Summary Consolidated Unaudited Balance Sheet Information (Unaudited - in thousands) ---------------------------------------------------------------------- September December 30, 31, 2007 2006 --------------------------------------------------- --------- -------- Current Assets(a) $6,361 $7,857 --------------------------------------------------- --------- -------- Current Liabilities $1,931 $2,213 --------------------------------------------------- --------- -------- Total Stockholders' Equity $4,831 $5,948 --------------------------------------------------- --------- -------- (a)Cash on hand at September 30, 2007 is $1.168 million.

SOURCE: MFIC Corporation

MFIC Corporation Jack M. Swig, 617-969-5452 [e-mail] or MacDougall Biomedical Communications Sarah Cavanaugh, 508-647-0209 [e-mail]

[cfoofme]

Microfluidics To Unveil New M-110P Microfluidizer® Processor At AAPS 2007
11/7/2007




Microfluidics will unveil its newest portable M-110P Microfluidizer® processor, a bench top lab machine that requires no compressed air or cooling water, at the 2007 AAPS Annual Meeting and Exposition in San Diego, CA from November 12-14.

Utilizing Microfluidics’ fixed geometry diamond interaction chamber technology and ceramic plunger, the M-110P easily enables the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption with the fewest number of passes. Additionally, the M-110P allows flow rates between 110-155 ml/minute at any process pressure, which is a higher flow rate than any comparable, competitive product. This flow rate enables the efficient processing of pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P machine are guaranteed to be scaleable to pilot and/or production volumes.

The M-110P comes with a programmable logic controller (PLC) that manages on board operation including audio-visual alarms, alarm acknowledgment and silencing, and motor starter interlocks. In the event that an operating parameter is out of tolerance, this PC-based system will alert users to respond. The PLC also makes available 10 digital I/O connections, as well as an analog channel for added flexibility. Each processor can be customized depending on specific formulation parameters and is available with options for external controls, such as automated alarms and auto shutdown. Additionally, the M-110P offers options for the internal and external monitoring of several variables including temperature and pressure.

The M-110P can be fitted with optional communication modules that allow the operator to monitor and control the M-110P remotely as in a factory automation setting.

About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.

Source: Microfluidics


Forward This Article To An Associate

[shmoopy38]

New Taglich Bros. research report:

http://www.taglichbrothers.com/equityuniverse/companies/mficcorp/mficcorp-09242007.pdf

[shmoopy38]

MFIC Corporation Announces Resignation of Irwin Gruverman from Board of Directors

NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC) announced today that Irwin J. Gruverman has resigned as a Director of MFIC effective Monday September 17, 2007.

Mr. Gruverman founded MFIC in 1982. Over the course of almost twenty five years, he served as CEO and Chairman until retiring in April 2007 and assuming the role of Chairman Emeritus on the Company’s Board of Directors.

“Under Irv’s vision and leadership, MFIC built a company that today leads the industry in high-shear processing equipment,” said James N. Little, Ph.D., Acting Chairman of MFIC. “We are very grateful for his many years of service to MFIC and I am joined by the other directors in wishing him very well in pursuing his other interests.”

About MFIC Corporation:

MFIC Corporation, through its operating subsidiary, Microfluidics Corporation, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

[cfoofme]

This cant hurt IMO.

[shmoopy38]

Para Ventures Corporation To Distribute Microfluidics Products
pharmaceuticalonline.com
September 17, 2007

Microfluidics announces the addition of Para Ventures Corporation, a manufacturer's representative agency headquartered in Los Angeles, Calif., to its team of North American sales representatives.

Since its establishment in 1995, Para Ventures has been an independent manufacturers' representation company that provides high quality products and services to the medical device, biomedical, pharmaceutical, diagnostic, semi-conductor, environmental and petro-chemical industries. Additionally, micro-fluidic consulting services as well as specialized products are also provided.

"We at Para Ventures are very excited to have joined the Microfluidics family," said Tom Costa, owner and founder of Para Ventures Corporation. "We look forward to working with such a well-known company and being able to provide our customers with Microfluidics’ unique high performance laboratory equipment."

About Microfluidics

Microfluidics provides patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries. Microfluidics applies its nearly 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics equipment customers.

Companies seeking an affordable, high-pressure fluid processor can get complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.

Source: Microfluidics

[willy1015]

I am a big buyer at these levels. VERY little downside.

[shmoopy38]

MFIC Corporation Introduces New Product, M-110P Microfluidizer(R) Processor
September 6, 2007 3:00 PM EDT
NEWTON, Mass.--(BUSINESS WIRE)--

MFIC Corporation (OTCBB: MFIC), an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries announced today the introduction by its operating subsidiary, Microfluidics Corporation, of the M-110P Microfluidizer laboratory scale processor. The M-110P, the Company's first portable bench top plug and play unit, can easily be incorporated into any laboratory setting because it is powered by only standard 20 amp household electrical current and requires no compressed air or cooling water. These features of the M-110P provide a critical formulation solution to customers who have been unable to test and formulate products in the past because they lacked the onsite systems requirements needed to allow them to operate small air operated laboratory units or the three phase electrical requirements needed to operate larger volume laboratory equipment.

The M-110P was designed to operate reliably, quietly and efficiently through a range of operating pressures from 2,000 psi to 30,000 psi, easily enabling the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption. Importantly, the M-110P also allows for higher flow rates - between 110-155 ml/minute at any process pressure - than any comparable, competitive product, allowing for the production of more sophisticated products including pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P are guaranteed to be scaleable to pilot and/or production volumes, allowing even the smallest customers the ability to fully develop, test, manufacture and produce their products.

"We think the M-110P will play an important role in our long-term growth strategy," said Robert Bruno, President and Chief Operating Officer of MFIC Corporation. "The introduction of the M-110P continues to position MFIC as the industry leader in providing formulation solutions and allows us to reach out to a larger customer base than we have been able to serve previously."

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer(R) materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.

Source: MFIC Corporation

[shmoopy38]

MFIC Corporation Subsidiary, Microfluidics, Receives 2007 Nano 50(TM) Technology Award
Tuesday August 28, 2:16 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News), an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries announced today that its wholly owned subsidiary, Microfluidics, has been named a technology category winner in the third annual Nanotech Briefs® Nano 50(TM) Awards. Microfluidics received the award for its revolutionary new Microfluidics Reaction Technology (MRT)--a next-generation approach in the production of nanosuspensions to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs.

The Nano 50 recognizes the top 50 technologies, products, and innovators that have significantly impacted, or are expected to impact, the state-of-the-art in nanotechnology. The recipients of the Nano 50 awards comprise the innovative people and designs that will move nanotechnology to key mainstream markets. Nano 50 nominations were judged by a panel of nanotechnology experts.

"The advent of MRT could potentially unlock drugs, vaccines and drug delivery systems that to date could not be formulated," said Dr. Thomai Panagiotou, Vice President of Research and Development at Microfluidics and head of the Company's MRT program. "MRT provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader. We anticipate introducing a new line of equipment to facilitate the MRT process late in the fourth quarter of this year or early in the first quarter of 2008, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."

About Microfluidics Reaction Technology (MRT):

MRT enables the manufacture of nanosuspensions in a "bottom up" fashion, utilizing chemical reactions and physical processes like crystallization. It has been proven effective for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes can reduce particle sizes, often to the nano-level, through a process of wet-milling, homogenization, micronization, and other techniques. However, there is an absolute limit as to how small top-down processes can reduce particle sizes and it often requires considerable effort, energy and repetitive processing cycles to achieve these levels of reduction.

MRT works by pumping liquid reactants to a Microfluidizer® processor reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location and has been demonstrated to be more effective in producing nanosuspensions than standard, top-down particle size reducing methods. This process is exceptional for a broad range of applications that require either fast or slow chemical reactions.

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.



Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
[e-mail]
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
[e-mail]

--------------------------------------------------------------------------------
Source: MFIC Corporation

[shmoopy38]

Microfluidics To Unveil New M-110p Microfluidizer Processor At Nanotx 2007

Date announced: 23 Aug 2007

For More Information, Visit Booth # 823

Newton, Mass. – Microfluidics will unveil its newest portable M-110P Microfluidizer® processor, a bench top lab machine that requires no compressed air or cooling water, at the nanoTX ‘07 Conference and Exhibition from October 2-4 in Dallas, TX.

Utilizing Microfluidics’ fixed geometry diamond interaction chamber technology and ceramic plunger, the M-110P easily enables the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption with the fewest number of passes. Additionally, the M-110P allows flow rates between 110-155 ml/minute at any process pressure, which is a higher flow rate than any comparable, competitive product. This flow rate enables the efficient processing of pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P machine are guaranteed to be scaleable to pilot and/or production volumes.

The M-110P comes with a programmable logic controller (PLC) that manages on board operation including audio-visual alarms, alarm acknowledgment and silencing, and motor starter interlocks. In the event that an operating parameter is out of tolerance, this PC-based system will alert users to respond. The PLC also makes available 10 digital I/O connections, as well as an analog channel for added flexibility. Each processor can be customized depending on specific formulation parameters and is available with options for external controls, such as automated alarms and auto shutdown. Additionally, the M-110P offers options for the internal and external monitoring of several variables including temperature and pressure.

MORE

The M-110P can be fitted with optional communication modules that allow the operator to monitor and control the M-110P remotely as in a factory automation setting.

About Microfluidics

Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.

Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities.

Contact
800-370-5452
E-mail: [e-mail]
Web site: http://www.microfluidicscorp.com

[shmoopy38]

MFIC Corporation Announces Second Quarter Financial Results
Tuesday August 14, 12:46 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News) today reported financial results for the quarter ended June 30, 2007. MFIC is an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.

MFIC reported that for the second quarter ended June 30, 2007, the company posted revenues of approximately $3.6 million compared to approximately $3.9 million during the second quarter of 2006, representing a decrease of approximately 9%.

"Although the first two quarters did not meet our expectations, we are beginning to see signs of improved performance. In July we secured orders for several large production units from new customers and we are seeing an increasing number of requests for quotations for our new standard biopharmaceutical pilot units and our production Microfluidizer® processor systems. Also, our new Microfluidics Technology Center is conducting sample tests at a level that is equivalent with the record-setting rate of 2006 and past experience has demonstrated that approximately 30% of all sample tests result in sales of equipment within two years," stated Robert P. Bruno, President and Chief Operating Officer of MFIC Corporation. "We are also looking forward to the upcoming launch of our new M-110P in the third quarter, a benchtop plug and play unit that provides a formulation solution for customers lacking the laboratory requirements needed to operate some of our larger pieces of equipment."

For the second quarter ended June 30, 2007, the Company posted a net loss of $107,000, or $.01 per diluted share, as compared with net income of $128,000, or $0.01 per diluted share, for the quarter ended June 30, 2006. The second quarter 2007 results included no income tax provision while the second quarter of 2006 included an income tax expense of $86,000.

Operating expenses increased by $332,000, or 18% to $2.2 million for the quarter ended June 30, 2007 from $1.9 million for the quarter ended June 30, 2006. The increase was primarily due to commission expenses resulting from an increase in sales by direct and indirect sales representatives, non-cash stock-based compensation in accordance with SFAS 123R and additional staffing and programs initially undertaken in 2005 to grow the business, including, but not limited to additional facilities space and expense, investment in research and discovery, the hiring of additional salespeople in key markets and an increase in sales related marketing and advertising expense.

The Company's order backlog at June 30, 2007 was $3 million compared to backlogs of $3.4 million and $2.9 million on June 30, 2006 and March 31, 2007, respectively. Backlog represents orders in hand that typically take between one and six months to deliver, with the exception of a chamber supply order scheduled to ship over a longer period.

For the six-month period ended June 30, 2007, revenues decreased by $703,000, or 10%, to approximately $6.4 million, and the Company reported a net loss of $0.05 per share, as compared with approximately $7 million in revenues, and a net profit of $0.02 per share, for the first six months of 2006.

During the second quarter 2007 MFIC Corporation accomplished several significant milestones:

Opened the Microfluidics Technology Center, which serves as an innovation hub for the Company's highly-specialized research team.
Retained an executive search firm to fill the CEO position.
Presented data supporting the significance of Microfluidics Reaction Technology (MRT) during a poster presentation at the Nano Science and Technology Institute (NSTI) Nanotech 2007 Conference.

"We've put multiple factors in play to support long-term revenue growth," said James Little, Acting Chairman of MFIC Corporation. "We've established a global brand and built a top-name customer base. Our investment in research and discovery has been fruitful and in the next six months, we hope to introduce two new product solutions to the market. We look forward to continuing to lead the market in high-value formulation and cell disruption equipment."

Notice to Investors/Stockholders:

MFIC will hold a conference call at 4:00 PM Eastern Time on Tuesday, August 14, 2007 to discuss second quarter financial results. Management's discussion will be followed by a question and answer period. Participants are invited to attend the call by visiting www.mficcorp.com or by dialing:

866-543-6411 (International: 617-213-8900)

Passcode: 43089243

For those who cannot listen and participate in the live event, a replay of the call will be available on the Company's website: www.mficcorp.com. A re-broadcast of the conference call will also be available until August 28, 2007 by dialing:

888-286-8010 (International: 617-801-6888)

Passcode: 10716893

About MFIC Corporation:

MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.

Forward Looking Statement:

Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.

Financial Charts Follow--
MFIC Corporation
Condensed Consolidated Statements of Operations
(Unaudited - in thousands, except per share amounts)

For The Three For The Six
Months Ended Months Ended
June 30, June 30,
-----------------------------------
2007 2006 2007 2006
-------- -------- -------- --------

Revenues $ 3,557 $ 3,910 $ 6,358 $ 7,061
Cost of sales 1,453 1,801 2,646 3,248
-------- -------- -------- --------
Gross profit 2,104 2,109 3,712 3,813
-------- -------- -------- --------
Operating expenses:
Research and development 438 453 974 850
Selling 984 741 1,808 1,357
General and administrative 805 701 1,483 1,323
-------- -------- -------- --------
2,227 1,895 4,265 3,530
-------- -------- -------- --------
(Loss) income from operations (123) 214 (553) 283
Interest expense (1) (10) (9) (20)
Interest income 17 10 38 20
-------- -------- -------- --------
(Loss) income before income tax
provision (107) 214 (524) 283
Income tax provision - 86 - 113
-------- -------- -------- --------
Net (loss) income $ (107) $ 128 $ (524) $ 170
======== ======== ======== ========
Net (loss) income per common
share:
Basic $ (0.01) $ 0.01 $ (0.05) $ 0.02
Diluted $ (0.01) $ 0.01 $ (0.05) $ 0.02
Weighted average number of common
and
common equivalent shares
outstanding:
Basic 10,180 9,974 10,152 9,963
Diluted 10,180 10,990 10,152 11,038

Summary Consolidated Unaudited Balance Sheet Information
(Unaudited - in thousands)
-------------------------------------------------------------------
June 30, December 31,
2007 2006
------------------------- -------------------- --------------------
Current Assets(a) $6,731 $7,857
------------------------- -------------------- --------------------
Current Liabilities $1,508 $2,213
------------------------- -------------------- --------------------
Total Stockholders'
Equity $5,628 $5,948
------------------------- -------------------- --------------------

(a) Cash on hand at June 30, 2007 is $1.3 million.



Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
E-mail: [e-mail]
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
E-mail: [e-mail]

--------------------------------------------------------------------------------
Source: MFIC Corporation